Financial Analysis: INVO Bioscience (NASDAQ:INVO) & Autonomix Medical (NASDAQ:AMIX)

Autonomix Medical (NASDAQ:AMIX) and INVO Bioscience (NASDAQ:INVO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, valuation and earnings.

Profitability

This table compares Autonomix Medical and INVO Bioscience’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Autonomix Medical	N/A	-212.48%	-161.13%
INVO Bioscience	-122.79%	N/A	-36.94%

Insider & Institutional Ownership

10.8% of Autonomix Medical shares are owned by institutional investors. Comparatively, 12.0% of INVO Bioscience shares are owned by institutional investors. 32.4% of Autonomix Medical shares are owned by insiders. Comparatively, 3.5% of INVO Bioscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Risk & Volatility

Autonomix Medical has a beta of -5.4, indicating that its share price is 640% less volatile than the S&P 500. Comparatively, INVO Bioscience has a beta of 1.43, indicating that its share price is 43% more volatile than the S&P 500.

Valuation and Earnings

This table compares Autonomix Medical and INVO Bioscience”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Autonomix Medical	N/A	N/A	-$15.43 million	($12.93)	-0.16
INVO Bioscience	$5.77 million	1.81	-$8.03 million	N/A	N/A

INVO Bioscience has higher revenue and earnings than Autonomix Medical.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Autonomix Medical and INVO Bioscience, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autonomix Medical	0	0	1	0	3.00
INVO Bioscience	0	0	0	0	0.00

Autonomix Medical presently has a consensus target price of $28.00, suggesting a potential upside of 1,279.31%. Given Autonomix Medical’s stronger consensus rating and higher probable upside, equities analysts clearly believe Autonomix Medical is more favorable than INVO Bioscience.

Summary

INVO Bioscience beats Autonomix Medical on 6 of the 11 factors compared between the two stocks.

About Autonomix Medical

Autonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.

About INVO Bioscience

INVO Bioscience, Inc., together with its subsidiary, a healthcare services fertility company, provides assisted reproductive technology solutions worldwide. It offers INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman’s body. The company was founded in 2007 and is based in Sarasota, Florida.